Form 4: Amneal EVP Boyer Vests Over 500K Shares

Amneal Pharmaceuticals Executive Vice President Andrew S. Boyer acquired over 500,000 shares through restricted stock unit vesting, including performance-based units that vested at 200% of target.

Summary

• Andrew S. Boyer, Executive Vice President of Amneal Pharmaceuticals, Inc. (AMRX), acquired a total of 548,953 shares of Class A Common Stock through the vesting of restricted stock units (RSUs) and performance-based restricted stock units (PBRSUs) on March 3 and March 4, 2026.
• A significant portion, 397,554 shares, resulted from performance-based restricted stock units granted on March 3, 2023, which vested at 200% of the targeted number due to the Issuer's Class A Common Stock achieving certain average closing prices over a three-year performance period.
• To satisfy tax withholding obligations related to these vestings, a total of 275,307 shares were disposed of at prices of $13.31 and $13.3 per share.
• Following these transactions, Boyer directly beneficially owns 426,072 shares of Class A Common Stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively as the significant vesting of performance-based restricted stock units at 200% of target indicates strong company performance against key stock price metrics, reflecting positively on executive incentives and shareholder value.

Positives

• Performance-based restricted stock units vested at 200% of the targeted number, indicating strong achievement of performance thresholds related to the Issuer's Class A Common Stock average closing prices.
• The vesting of a substantial number of shares (548,953 gross shares) demonstrates significant long-term incentive compensation for a key executive.

Negatives

• A considerable number of shares (275,307) were withheld to cover tax obligations, representing a disposition of stock rather than an increase in direct beneficial ownership for those specific shares.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that executive compensation through equity awards, particularly performance-based units, is a common practice in the pharmaceutical industry to align management incentives with shareholder value creation. The achievement of a 200% vesting threshold for performance-based units suggests the company met or exceeded specific stock price targets, which is a positive indicator for the company's market performance during the relevant period.

Comparison to Industry Standards

• StockSavvy.ai observes that the use of restricted stock units (RSUs) and performance-based restricted stock units (PBRSUs) as a significant component of executive compensation is standard across the pharmaceutical and broader corporate sectors.
• The 200% vesting of performance-based units for Amneal Pharmaceuticals' EVP, Andrew S. Boyer, indicates strong performance against pre-defined metrics, which compares favorably to companies where performance targets are merely met or partially achieved. For example, while many companies like Pfizer or Johnson & Johnson utilize similar equity incentive structures, the specific achievement of 200% of target for PBRSUs suggests Amneal's stock performance during the three-year period exceeded internal benchmarks, potentially outperforming peers who might have only achieved 100-150% of their performance targets for similar grants.

Related Party Transactions

• The transactions involve the vesting of equity awards granted by Amneal Pharmaceuticals, Inc. to its Executive Vice President, Andrew S. Boyer, which are standard compensation arrangements between an executive and the company.

Stakeholder Impact

• Shareholders: The vesting of performance-based units at 200% suggests strong stock performance, which is beneficial for shareholders. The increased ownership by an executive aligns interests.
• Employees: Demonstrates the company's commitment to executive incentive programs, potentially signaling a stable and rewarding environment for key personnel.

Next Steps

• The remaining unvested portions of the RSU grants from March 4, 2022, March 3, 2023, March 3, 2025, and March 4, 2024, will continue to vest in equal installments on their respective anniversaries of the grant dates.

Key Dates

Recommendation

While the 200% vesting of performance-based units is a positive indicator of past stock performance and executive alignment, this Form 4 primarily details routine compensation events. It does not provide new fundamental information to warrant a 'buy' or 'sell' recommendation based solely on this filing. Investors should 'hold' and consider this information in conjunction with broader financial reports and strategic updates.

Keywords

Amneal Pharmaceuticals, AMRX, Andrew S. Boyer, SEC Form 4, Insider Transaction, Restricted Stock Units, Performance-Based RSUs, Executive Compensation, Stock Vesting, Tax Withholding